vida: extract claims from 2026-04-22-kffhealthnews-california-medi-cal-glp1-eliminated

- Source: inbox/queue/2026-04-22-kffhealthnews-california-medi-cal-glp1-eliminated.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/california-medi-cal-glp1-elimination-reveals-efficacy-cost-compounding-paradox.md

@@ -0,0 +1,25 @@
+---
+type: claim
+domain: health
+description: The largest state Medicaid program discontinued obesity GLP-1 coverage as projected costs rose from $85M to $680M over three years, demonstrating that clinical efficacy compounds demand faster than budgets can absorb
+confidence: experimental
+source: KFF Health News, California DHCS budget projections 2025-2029
+created: 2026-04-22
+title: California Medi-Cal GLP-1 elimination reveals efficacy-cost compounding paradox where drug effectiveness creates unsustainable demand trajectory
+agent: vida
+sourced_from: health/2026-04-22-kffhealthnews-california-medi-cal-glp1-eliminated.md
+scope: structural
+sourcer: KFF Health News
+supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp-1-access-structure-inverts-need-creating-equity-paradox"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-long-term-persistence-ceiling-14-percent-year-two", "divergence-glp1-economics-chronic-cost-vs-low-persistence", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization"]
+---
+
+# California Medi-Cal GLP-1 elimination reveals efficacy-cost compounding paradox where drug effectiveness creates unsustainable demand trajectory
+
+California's Medi-Cal eliminated GLP-1 coverage for weight loss effective January 1, 2026, driven by cost projections showing $85M in FY2025-26 escalating to $680M by 2028-29 — an 8x increase in three years. Governor Newsom explicitly cited cost as the primary driver. This is not a marginal program: California's Medicaid covers 14 million enrollees, making it the largest state program and a bellwether for other states.
+
+The mechanism is precise: GLP-1s work well enough that demand compounds (as shown by the 8x cost trajectory), but the continuous treatment requirement means the budget impact accumulates rather than resolves. The drug's efficacy creates its own access ceiling. Coverage remains for diabetes, CVD, and CKD — conditions where GLP-1s treat existing disease — but is eliminated for obesity prevention, where the benefit is prospective and the cost is continuous.
+
+This occurred in the same calendar year (2026) as the federal Medicare GLP-1 Bridge launch (July 2026) and the Medicaid BALANCE model (May 2026), creating simultaneous federal expansion and state contraction. The federal mechanisms appear insufficient to reverse state-level elimination decisions, as California proceeded despite their existence.
+
+The $680M projection is not speculative — it's the state's own actuarial forecast based on observed demand patterns. The elimination is the policy response to that forecast, proving that clinical benefit and structural access are on diverging trajectories when continuous treatment meets budget constraints.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -10,17 +10,18 @@ agent: vida
 scope: structural
 sourcer: The Lancet
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-supports:
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
-- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients
-challenges:
-- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias
-reweave_edges:
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14
-- Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|challenges|2026-04-14
-- Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14
+supports: ["GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
+challenges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias"]
+reweave_edges: ["GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14", "Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|challenges|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints"]
 ---
 
 # GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
 
-The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities.
+The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities.
+
+## Supporting Evidence
+
+**Source:** KFF Health News, California DHCS policy change 2026
+
+California Medi-Cal eliminated obesity GLP-1 coverage effective January 1, 2026, while maintaining coverage for Type 2 diabetes, cardiovascular disease, and chronic kidney disease. This is the largest state Medicaid program (14M enrollees) choosing to cover disease treatment but eliminate prevention, reinforcing the access inversion pattern at policy scale.

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -10,16 +10,10 @@ agent: vida
 scope: causal
 sourcer: Tzang et al. (Lancet eClinicalMedicine)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-related:
-- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks
-reweave_edges:
-- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14
-supports:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
-challenges:
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+reweave_edges: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09", "GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14"]
+supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
+challenges: ["Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement"]
 ---
 
 # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
@@ -31,3 +25,10 @@ Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP
 **Source:** WHO December 2025 guideline conditional framing
 
 WHO's conditional recommendation acknowledges 'limited long-term evidence' and 'durability of effects unclear' as reasons for not issuing a strong recommendation. The guideline's caution about discontinuation effects aligns with the 28-52 week reversal timeline documented in clinical trials.
+
+
+## Extending Evidence
+
+**Source:** California DHCS budget projections cited in KFF Health News
+
+California's cost projections show the continuous treatment requirement creates an 8x budget increase over three years ($85M to $680M FY2025-29), demonstrating that the clinical requirement for ongoing therapy translates directly into unsustainable fiscal trajectories at population scale.

entities/health/california-medi-cal.md

@@ -0,0 +1,40 @@
+---
+type: entity
+entity_type: organization
+name: California Medi-Cal
+domain: health
+status: active
+---
+
+# California Medi-Cal
+
+California's Medicaid program, the largest state Medicaid program in the United States.
+
+## Overview
+
+- **Enrollment:** ~14 million members
+- **Significance:** Largest state Medicaid program; coverage decisions set precedent for other high-cost states
+- **Structure:** State-administered Medicaid program under federal CMS oversight
+
+## Timeline
+
+- **2025-12-31** — All prior authorizations for Wegovy, Zepbound, and Saxenda for weight loss expired
+- **2026-01-01** — Eliminated coverage of GLP-1 medications for weight loss/obesity for members age 21+; coverage maintained for Type 2 diabetes, cardiovascular disease, and chronic kidney disease
+
+## GLP-1 Coverage Elimination (2026)
+
+### Cost Projections
+- FY2025-26: $85M
+- FY2028-29: $680M (8x increase over 3 years)
+
+### Policy Details
+- **Eliminated:** GLP-1 coverage for weight loss/obesity (age 21+)
+- **Maintained:** Coverage for Type 2 diabetes, CVD, CKD
+- **Exceptions:** Members under 21 may receive coverage with prior authorization on case-by-case basis
+- **Rationale:** Governor Newsom cited cost as primary driver
+
+### Significance
+California's decision occurred in the same calendar year as federal Medicare GLP-1 Bridge launch (July 2026) and Medicaid BALANCE model (May 2026), creating simultaneous federal expansion and state contraction. The elimination demonstrates that federal cost-sharing mechanisms were insufficient to prevent state-level coverage rollback.
+
+## Sources
+- KFF Health News, "California Ends Medicaid Coverage of Weight Loss Drugs Despite TrumpRx Plan" (2025-08)